Evidence map›Paper›PMID 42861285›Full record

ReviewFrontiers in toxicology2026

Phytocannabinoid-drug interactions: pharmacokinetic and pharmacodynamic mechanisms, clinical relevance and toxicological considerations.

Diogo Alexandre Gomes, Wellyngton Vieira Eufrázio, Marcella Silva Ribeiro, Linério Ribeiro de Novais Júnior, Flávia Rigo, Patrícia de Aguiar Amaral, Antonella Campanale, Antônio Inserra, Rafael Mariano de Bitencourt

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Diogo Alexandre Gomes *Behavioral Neuroscience Laboratory, Postgraduate Program in Health Sciences, University of Southern Santa Catarina (UNISUL), Tubarão, Brazil.
Wellyngton Vieira Eufrázio *Behavioral Neuroscience Laboratory, Postgraduate Program in Health Sciences, University of Southern Santa Catarina (UNISUL), Tubarão, Brazil.
Marcella Silva RibeiroBehavioral Neuroscience Laboratory, Postgraduate Program in Health Sciences, University of Southern Santa Catarina (UNISUL), Tubarão, Brazil.
Linério Ribeiro de Novais JúniorBehavioral Neuroscience Laboratory, Postgraduate Program in Health Sciences, University of Southern Santa Catarina (UNISUL), Tubarão, Brazil.
Flávia RigoMedicinal Plant Laboratory (LaPlaM), Postgraduate Program in Health Sciences, University of the Extreme South of Santa Catarina (UNESC), Criciúma, Brazil.
Patrícia de Aguiar AmaralMedicinal Plant Laboratory (LaPlaM), Postgraduate Program in Health Sciences, University of the Extreme South of Santa Catarina (UNESC), Criciúma, Brazil.
Antonella CampanaleBehavioral Neuroscience Laboratory, Postgraduate Program in Health Sciences, University of Southern Santa Catarina (UNISUL), Tubarão, Brazil.
Antônio InserraBehavioral Neuroscience Laboratory, Postgraduate Program in Health Sciences, University of Southern Santa Catarina (UNISUL), Tubarão, Brazil.
Rafael Mariano de BitencourtBehavioral Neuroscience Laboratory, Postgraduate Program in Health Sciences, University of Southern Santa Catarina (UNISUL), Tubarão, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic use of phytocannabinoids has expanded considerably over the past decade because of their potential application across a wide range of clinical conditions. However, their concomitant use with conventional medications raises important concerns regarding drug interactions and patient safety. This narrative review provides a critical overview of current evidence on the pharmacokinetic (PK), pharmacodynamic, and toxicological interactions of major phytocannabinoids, with particular emphasis on cannabidiol (CBD) and Δ

Indexed as

cannabidiolcytochrome P450drug-drug interactionspharmacokineticsphytocannabinoidstoxicologyΔ9-tetrahydrocannabinol

Identifiers

PMID42861285
PMCPMC13654618

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.